Skip to content

PHARMA MANUFACTURING

Active
Public limited companyfounded 2001active for 25 yearsRue Guillaume Fouquet,Isnes 16, 5032 Gembloux, BelgiumKBO/BCE: BE 0475.313.955
Summary

PHARMA MANUFACTURING has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.8m and a net result of €6,229. Equity is growing by about 3.5% per year across the filed financial years. Its solvency ranks better than 95% of 788 sector peers (NACE 10, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).

Risk analysisFollow ReportCompare
PHARMA MANUFACTURINGActiveChecked score 71/100
Risk analysis ReportCompare

Overview

Activity
Manufacture of food products
NACE 10860Office administrative, office support and other business support activities NACE 82920
4th largest company by equity in the province of Namur, Food products sector1 site
Size
€3.0mturnover 2025
Staff
11.3 FTE
Equity
€2.8m
Profit
€6,229
Financial health
71 Healthy Checked score 2025
Bankruptcy probabilitywithin 12 months
0.6%
Structure
Largest shareholder
AVIXIA · 10%
Board
4 members
2025 accounts filed 61 days late1 of 5 deeds summarised
Why 71raises riskLast filed accounts filed 61 days late; 3 of the last 3 lateSector: Manufacture of food products (NACE 10)lowers riskFounded in 2001Equity €2.8m (93.1% of total assets)Show the evidence

Checked score

Score 2025
71 / 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 63% of its sector peers (NACE 10, small)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 100=
equity 93.1% of total assets
Liquidity 53+1
short-term debt 6.9% · cash 2.6%
Profitability 59-2
return on assets 0.2%
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%

About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (630 companies, NACE 10, small)
Last 24 months 11-2024: 0.9% 12-2024: 0.9%● unchanged vs 11-2024 01-2025: 0.9%● unchanged vs 12-2024 02-2025: 0.9%● unchanged vs 01-2025 03-2025: 1.0%▲ +0.1 percentage points vs 02-2025 04-2025: 1.0%● unchanged vs 03-2025 05-2025: 1.0%● unchanged vs 04-2025 06-2025: 1.0%● unchanged vs 05-2025 07-2025: 1.1%▲ +0.1 percentage points vs 06-2025 08-2025: 1.4%▲ +0.3 percentage points vs 07-2025 09-2025: 1.6%▲ +0.2 percentage points vs 08-2025highest value 10-2025: 0.8%▼ -0.8 percentage points vs 09-2025 11-2025: 0.8%● unchanged vs 10-2025 12-2025: 0.8%● unchanged vs 11-2025 01-2026: 0.8%● unchanged vs 12-2025 02-2026: 0.8%● unchanged vs 01-2026 03-2026: 0.9%▲ +0.1 percentage points vs 02-2026 04-2026: 0.9%● unchanged vs 03-2026 05-2026: 1.0%▲ +0.1 percentage points vs 04-2026 06-2026: 1.0%● unchanged vs 05-2026 07-2026: 1.0%● unchanged vs 06-2026 08-2026: 1.4%▲ +0.4 percentage points vs 07-2026 09-2026: 1.5%▲ +0.1 percentage points vs 08-2026 10-2026: 0.6%▼ -0.9 percentage points vs 09-2026lowest value
Credit of up to €190,000 on 30-day terms is acceptable
Liquidity ample (current ratio 13.2, compared with 10.35 in 2024, above the usual 1.5; short-term debt: 6.9% and cash: 2.6% of total assets), and 6.9% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 10, small): better than 95% on solvency, 69% on liquidity, 31% on profitability and 55% on growth.

The bankruptcy probability was computed on 30-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises risk
raises risk · Last filed accounts filed 61 days late; 3 of the last 3 late
NBB · filings
raises risk · Sector: Manufacture of food products (NACE 10)
KBO
lowers risk · Founded in 2001
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Equity €2.8m (93.1% of total assets)
NBB · annual accounts
raises risk · 2025 accounts filed 61 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-09-2026, 61 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
61 days late
2024
61 days late
2023
74 days late
2022
113 days late
2021
78 days late
2020
60 days late
2019
140 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 84 days after the deadline; the sector median (NACE 10) for financial year 2024 is 4 days before the deadline, and 38% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 14 October (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
31-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Annual accounts filedfinancial year 2024 · full…
  3. Annual accounts filedfinancial year 2023 · full…

Key points

  • Positive: Among the best 5% on solvencysector median 39.7% · 788 companies 93.1% View
  • Caution: Latest accounts filed lateafter the legal deadline 61 days View
  • Known shareholdersaccounts at 31-12-2025 100% View

By topic

Financials

Financial year
2025
Turnover
€3.0m
Profit
€6,229
Solvency
93.1%
Turnover▲ 8.5%
Net result
20192025
Go to Financials

Board & ownership

Board
4 members
Largest shareholder
AVIXIA · 10%
Known shareholders
100%
  • GENETTE HuguesManaging director
  • GENETTE Jean-CharlesManaging director
  • GENETTE OlivierManaging director
  • GENETTE PhilippeManaging director
Go to Board & ownership

Timeline

Events
27
Since
2003
Next accounts
by 31-07-2027
  1. 16-05-2024Appointments: GENETTE Philippe, GENETTE Olivier and 2…
  2. 21-11-2023Annual accounts filed
  3. 31-12-2022Back to profit
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Manufacture of food productsNACE 10860
Founded
16-07-2001
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
45
Annual meeting
Third Thursday of June at 18:00
Purpose
“Le commerce sous toutes ses formes y compris l’importation,l’exportation,la…” (deed in French)
Go to Articles of association

Key facts about PHARMA MANUFACTURING

What is the company number of PHARMA MANUFACTURING?
0475.313.955. In Belgium the VAT number is the company number with BE in front: BE 0475.313.955.
Where is PHARMA MANUFACTURING based?
The registered office is at Rue Guillaume Fouquet,Isnes 16, 5032 Gembloux.Company details
What does PHARMA MANUFACTURING do?
According to the KBO register, the main activity is manufacture of food products (NACE 10860).
What is the legal form of PHARMA MANUFACTURING?
Public limited company (NV).
When was PHARMA MANUFACTURING founded?
On 16-07-2001.
Is PHARMA MANUFACTURING still active?
Yes, PHARMA MANUFACTURING is an active enterprise in the KBO register.
How many employees does PHARMA MANUFACTURING have?
On average 11.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of PHARMA MANUFACTURING?
€3.0m in financial year 2025, according to the filed annual accounts.
Is PHARMA MANUFACTURING profitable?
In financial year 2025, PHARMA MANUFACTURING made a profit of €6,229.
Where can I find the annual accounts of PHARMA MANUFACTURING?
PHARMA MANUFACTURING filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMA MANUFACTURING due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to PHARMA MANUFACTURING

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure